We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
REVIEW
Glucose metabolism and insulin resistance in sepsis.
Hyperglycemia is a common feature of the critically ill in general and of patients with sepsis in particular. Even a moderate degree of hyperglycemia appears detrimental for the outcome of critically ill patients, since maintenance of normoglycemia (blood glucose levels <or=110 mg/dL) with intensive insulin therapy has shown to improve survival and reduce morbidity in prolonged critically ill patients in both surgical and medical intensive care units, as revealed by two large randomized controlled studies. Subsequently, questions have been raised regarding the efficacy and safety of this intervention, above all in the major subpopulation of intensive care patients presenting with sepsis, who are particularly susceptible to hypoglycemia as well. Adequately powered and executed randomized controlled trials addressing explicitly the impact of hyperglycemia, tight blood glucose control and the inherently increased risk of hypoglycemia on mortality and morbidity in patients with sepsis are presently lacking. However, the available literature suggests a causal link between hyperglycemia and adverse outcome in sepsis and a benefit of intensive insulin therapy in sepsis equal to the benefit found in critical illness without sepsis and critical illness in general. Though a high frequency of hypoglycemia may be noted during insulin treatment of patients with sepsis, the present observations define hypoglycemia as a marker of disease severity rather than a harmful treatment side-effect. Prevention of cellular glucose toxicity by strict glycemic control appears to play a predominant role, but other metabolic and non-metabolic, anti-inflammatory effects of insulin seem to contribute to the clinical benefits realized.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app